

References

I-85

1. Tysabri (natalizumab) injection, for intravenous use [package insert]. Biogen Inc. Cambridge, MA. Revised 06/2020.
2. Corboy JR, Halper J, Langer-Gould AM, et al. Position Statement: Availability of Disease Modifying Therapies (DMT) for the Treatment of Relapsing Forms of Multiple Sclerosis. The American Academy of Neurology (AAN) and the National MS Society (NMSS). 2015.
3. Korzenik Natalizumab for treatment of Crohn's disease in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: *UpToDate*; updated January 6, 2015.
4. National Multiple Sclerosis Society. Multiple Sclerosis Information for Healthcare
5. Olek M. Natalizumab for relapsing-remitting multiple sclerosis in adults. In: UpToDate Online Journal [serial online]. Waltham, MA: *UpToDate*; updated October 7, 2016
6. Voloshyna N; Havrdová E; Hutchinson M; Nehrych T., et al. Natalizumab improves ambulation in relapsing remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. *European Journal Of Neurology* [Eur J Neurol], ISSN: 1468- 1331, 2015 Mar; Vol. 22 (3), pp. 570-7.
7. White, M., Sariyer, I., Gordon, J., et al. Diagnostic Assays for Polyomavirus JC and Progressive Multifocal Leukoencephalopathy. *Rev Med Virol*. 2016 March; 26(2): 102–114.
8. Brandstadter R, Sand IK. The use of natalizumab for multiple sclerosis. *Neuropsychiatric Disease and Treatment*. 2017;1691-1702.
9. Clerico M, Artusi CA, DiLiberto A, et al. Natalizumab in multiple sclerosis: long-term management. *Int J Mol Sci*. 2017; 18(5):940-952.
10. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Natalizumab.
11. Micromedex® Solutions Compendia. 2020. Natalizumab.

12. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet*. 2018. 17(2):162-173.
13. Bross M, Hackett M, Bernitsas E. Approved and emerging disease modifying therapies on neurodegeneration in multiple sclerosis. *International Journal of Molecular Sciences*. 2020;21(12):4312.
14. Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. *JAMA Neurology*. 2020;77(2):184-191.